UroGen Pharma (UR8) Stock Overview
A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
UR8 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
UroGen Pharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.00 |
| 52 Week High | US$33.40 |
| 52 Week Low | US$11.20 |
| Beta | 1.57 |
| 1 Month Change | 42.36% |
| 3 Month Change | 109.92% |
| 1 Year Change | 192.04% |
| 3 Year Change | 208.41% |
| 5 Year Change | 170.49% |
| Change since IPO | -29.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| UR8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.8% | -0.1% | 4.3% |
| 1Y | 192.0% | 17.2% | 2.9% |
Return vs Industry: UR8 exceeded the German Biotechs industry which returned 16.8% over the past year.
Return vs Market: UR8 exceeded the German Market which returned 2.9% over the past year.
Price Volatility
| UR8 volatility | |
|---|---|
| UR8 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: UR8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UR8's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 298 | Liz Barrett | www.urogen.com |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC.
UroGen Pharma Ltd. Fundamentals Summary
| UR8 fundamental statistics | |
|---|---|
| Market cap | €1.62b |
| Earnings (TTM) | -€116.44m |
| Revenue (TTM) | €122.79m |
Is UR8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UR8 income statement (TTM) | |
|---|---|
| Revenue | US$140.49m |
| Cost of Revenue | US$14.26m |
| Gross Profit | US$126.24m |
| Other Expenses | US$259.46m |
| Earnings | -US$133.22m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.73 |
| Gross Margin | 89.85% |
| Net Profit Margin | -94.83% |
| Debt/Equity Ratio | -152.5% |
How did UR8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 12:59 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UroGen Pharma Ltd. is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Jason Kolbert | D. Boral Capital LLC. |
| Paul Choi | Goldman Sachs |